THE TYSABRI CHANNEL
WE HAVE 2 NEW TYSABRI EDITORS STARTING 4/15/10! THEY WIL BE POSTING TYSABRI NEWS EVERY DAY!
Wednesday, May 14
Biogen Leverages Strength In MS Treatments
By the end of the third quarter, Biogen's multiple sclerosis treatments Avonex, Tysabri, and Tecfidera had racked up $3.94 billion in sales so far for the year — about 80% of total revenue.
5/14/2014 05:49:00 AM
Share to Twitter
Share to Facebook
Share to Pinterest